Standard BioTools Inc LAB Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.64 up $0.01, 2.19% at close Nov 6
Last close · Previous close $0.62
- Market cap
- $249.68MAt the Nov 6 close
- P/E ratio
- 1.87On last 12 months’ EPS
- Diluted EPS
- $0.34Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$0.64up $0.01, 2.19%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.62Nov 5
- Volume1.12MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume817.80KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.59 to $1.72; now $0.64
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
LAB trailed the S&P 500 in all 5 periods.
| Period | LAB and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | LAB: down 11.9% S&P 500: down 5.6% | LAB trailed the S&P 500 by 6.3 percentage points Trailed |
| 3M | LAB: down 20.5% S&P 500: down 4.1% | LAB trailed the S&P 500 by 16.4 percentage points Trailed |
| YTD | LAB: down 50.3% S&P 500: up 8.7% | LAB trailed the S&P 500 by 59.0 percentage points Trailed |
| 1Y | LAB: down 43.2% S&P 500: up 10.9% | LAB trailed the S&P 500 by 54.1 percentage points Trailed |
| Long term | ||
| 3Y | LAB: down 68.8% S&P 500: up 75.0% −32.2% vs +20.5% a year | LAB trailed the S&P 500 by 143.8 percentage points Trailed |
$10,000 invested in LAB a year ago (Nov 6, 2025) would be worth about $5,679 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $11,088.
LAB trailed the S&P 500 in all 5 periods.
| Period | LAB and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | LAB: down 11.9% S&P 500: down 5.6% | LAB trailed the S&P 500 by 6.3 percentage points Trailed |
| 3M | LAB: down 20.5% S&P 500: down 4.3% | LAB trailed the S&P 500 by 16.2 percentage points Trailed |
| YTD | LAB: down 50.3% S&P 500: up 7.8% | LAB trailed the S&P 500 by 58.1 percentage points Trailed |
| 1Y | LAB: down 43.2% S&P 500: up 9.7% | LAB trailed the S&P 500 by 52.9 percentage points Trailed |
| Long term | ||
| 3Y | LAB: down 68.8% S&P 500: up 68.8% −32.2% vs +19.1% a year | LAB trailed the S&P 500 by 137.6 percentage points Trailed |
$10,000 invested in LAB a year ago (Nov 6, 2025) would be worth about $5,679 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $10,969.
All-time high
$18.93
Closing high on . Now 96.6% below that record.
Split-adjusted daily closes since Jul 29, 2003.
Stock splits
LAB hasn’t split since its price history begins in 2003.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Sep 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
1.9×The Nov 6 close ÷ diluted EPS over the last 12 months ($0.34)
The range covers daily P/E ratios from Dec 31, 2021 to Nov 6, 2026, each based on the previous 12 months of earnings.
LAB trades at 1.9× its earnings over the last 12 months, below its 5-year median of 3.8×. In plain terms, buyers are paying about $2 for each $1 of profit from the past year. How to read P/E
Other valuation measures
- 3.0×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 0.4×Book value as of Sep 30, 2026
Price relative to accounting equity (book value) per share on the Sep 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - −1.7×Last 12 months’ EBITDA
Enterprise value divided by EBITDA over the last 12 months. It compares companies with different amounts of debt.
EV/EBITDA = Enterprise value ÷ EBITDA (last 12 months)EV/EBITDA explained - −26.29%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - −$184.60MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Sep 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own LAB DCF in Excel. Value Standard BioTools with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $84.43Mdown 2.2%
- Net income
- $133.08M
- Diluted EPS
- $0.34
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $24.78M | −$34.07M | −$0.08 |
| Q1 FY25 (Mar 31, 2025) | $20.22M | −$26.03M | −$0.07 |
| Q2 FY25 (Jun 30, 2025) | $21.76M | −$33.46M | −$0.09 |
| Q3 FY25 (Sep 30, 2025) | $19.55M | −$34.69M | −$0.09 |
| Q4 FY25 (Dec 31, 2025) | $23.80M | $19.28M | $0.05 |
| Q1 FY26 (Mar 31, 2026) | $21.15M | $127.07M | $0.33 |
| Q2 FY26 (Jun 30, 2026) | $20.10M | −$26.76M | −$0.07 |
| Q3 FY26 (Sep 30, 2026) | $19.39M | $13.48M | $0.03 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $130.58M | −$59.24M | −$0.78 |
| FY22 (Dec 31, 2022) | $97.95M | −$190.10M | −$2.43 |
| FY23 (Dec 31, 2023) | $106.34M | −$74.66M | −$0.94 |
| FY24 (Dec 31, 2024) | $91.01M | −$138.89M | −$0.52 |
| FY25 (Dec 31, 2025) | $85.33M | −$74.90M | −$0.20 |
Margins
- Gross 52.2%
- Operating −97.5%
- Net 157.6%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$65.65MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$64.26MLast 12 months
- Capital spending$1.39MLast 12 months
- −77.8%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $944.00KLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $559.35MAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$26.83MAs of Sep 30, 2026
- Net cash$532.52MAs of Sep 30, 2026
- 9.75As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.05As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 6 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✗Operating cash flow was positive: not passed
- ✓Return on assets improved: passed
- ✗Operating cash flow exceeded net income: not passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- 25.6%Last 12 months
Over the last 12 months, Standard BioTools’s net income was 25.6% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 21.6%Last 12 months
Over the last 12 months, Standard BioTools’s net income was 21.6% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
Dividends
Cash dividends per share by ex-dividend year, adjusted for splits.
Dividends per share
Data table
| Year | Per share |
|---|---|
| 2016 | $0.000 |
| 2017 | $0.000 |
| 2018 | $0.000 |
| 2019 | $0.000 |
| 2020 | $0.000 |
| 2021 | $0.000 |
| 2022 | $0.000 |
| 2023 | $0.000 |
| 2024 | $0.000 |
| 2025 | $0.000 |
| 2026 (to date) | $0.000 |
Dividend details
- $0.00Per share, last 12 months
Cash dividends per share with ex-dividend dates in the last 12 months.
- 0.00%; 5-yr low 2.04%, 5-yr high 8.57%Last 12 months
Dividends paid over the last 12 months as a share of the Nov 6 close. The bar shows where that yield sits in its range over the past five years; the median was 4.40%.
- $0.080Ex-dividend
The most recent payment per share. Shares bought on or after the ex-dividend date don’t receive it.
About Standard BioTools Inc
Standard BioTools Inc., has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Massachusetts, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
LAB news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
LAB stock FAQ
What is LAB stock’s price today?
Standard BioTools (LAB) traded at $0.64 at the close on , up $0.01 (2.19%) from the previous close of $0.62. Over the past 52 weeks it has traded between $0.59 and $1.72.
What is Standard BioTools’s market cap?
Standard BioTools’s market capitalization is about $249.7 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $0.64 (how market cap works). Standard BioTools reported 392.58M shares outstanding at the end of its latest quarter ().
What is LAB’s P/E ratio?
LAB trades at 1.9 times its diluted earnings over the four quarters to ($0.34 per share), at the close. Over the past five years its P/E has ranged from 1.8 to 6.3, with a median of 3.8. (How the P/E ratio works.)
How much revenue does Standard BioTools make?
Standard BioTools reported $84.4 million of revenue over the four quarters to , down 2.2% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $19.4 million, down 0.9% from a year earlier.
Is Standard BioTools profitable?
Yes. Standard BioTools earned $133.1 million of net income over the four quarters to , a net margin of 157.6%, and its operating margin was −97.5% (what margins tell you).
What are LAB’s earnings per share?
LAB’s diluted earnings per share were $0.34 over the four quarters to , compared with −$0.33 in the twelve months before. The latest quarter (Q3 FY26) brought $0.03 per share, against −$0.09 a year earlier (how EPS works).
Does LAB pay a dividend?
Standard BioTools hasn’t paid a dividend in the last twelve months.
What is LAB’s 52-week high and low?
Over the past 52 weeks LAB has traded as low as $0.59 and as high as $1.72. At $0.64 at the close on , it is 63.0% below that high and 8.1% above the low.
What is LAB’s all-time high?
LAB’s highest closing price was $18.93 on , adjusted for stock splits. At $0.64 at the close on , it is 96.6% below that record.
Has LAB stock ever split?
No. LAB hasn’t split since its price history begins in 2003.
How has LAB stock performed?
Including dividends and measured to the close on , LAB has returned −50.3% so far this year and −43.2% over the past year. Over the same periods the S&P 500, measured by SPY, returned +8.7% and +10.9%. Past performance doesn’t predict future returns.
What sector and industry is Standard BioTools in?
Standard BioTools is in the Healthcare sector and the Medical Devices industry, and is headquartered in Massachusetts, USA.
What exchange does LAB trade on?
Standard BioTools trades on the Nasdaq under the ticker symbol LAB. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.